RareMoon Consulting — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

RareMoon Consulting is a specialized regulatory services firm founded in 2016, with deep expertise in orphan drug designations and advanced therapeutic products like cell and gene therapies. It offers fractional regulatory leadership, submission support, and health agency meeting strategy to biotech and pharmaceutical clients, leveraging a team with a proven track record in expedited pathways. The company is privately held, mission-driven by the founders' personal connections to rare disease, and operates on a fee-for-service consulting model, positioning it as a strategic partner in the high-stakes rare disease development landscape.

Rare Disease

Technology Platform

Proprietary regulatory strategy methodologies and fractional service model for navigating orphan drug designations, expedited pathways (Breakthrough Therapy, RMAT), and global submissions for advanced therapies.

Opportunities

The rapid growth of the cell/gene therapy and rare disease drug development sectors creates increasing demand for specialized regulatory expertise.

The trend towards virtual biotech companies with lean internal teams expands the market for high-quality fractional regulatory services.

Globalization of drug development offers opportunities to broaden support beyond FDA/EMA to other key health authorities.

Risk Factors

Revenue is tied to biotech R&D spending, making it vulnerable to sector funding downturns.

The business is entirely dependent on retaining its key expert personnel, as its intellectual capital is its primary asset.

Intense competition from both large CROs and other boutique consultancies requires constant demonstration of superior value and expertise.

Competitive Landscape

RareMoon competes in the regulatory consulting niche against large global CROs (e.g., IQVIA, Parexel) that offer broad services and smaller boutique firms specializing in rare diseases or advanced therapies. Its differentiation lies in its deep, focused expertise in orphan drug/expedited pathways, a mission-driven culture, and a fractional service model offering senior-level partnership without full-time cost.

More companies in United Kingdom →